Correction (DOI:10.1016/j.otohns.2007.08.005);An assessment of the onset and duration of action of olopatadine nasal spray

Otolaryngology - Head and Neck Surgery

Volumn 137, Issue 6, 2007, Pages 918-924

  Patel, Piyush ^a   Roland, Peter S ^b   Marple, Bradley F ^b   Benninger, Paul J ^a   Margalias, Harriet ^a   Brubaker, Michael ^c   Beezley, Susan F ^c   Drake, Margaret ^c   Potts, Susan L ^c   Wall, G Michael ^c  

^a Allied Research International   (Canada)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c ALCON RESEARCH LTD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OLOPATADINE; PLACEBO; RAGWEED ANTIGEN;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENVIRONMENTAL EXPOSURE; FEMALE; HAY FEVER; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; NOSE IRRITATION; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SYMPTOMATOLOGY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 36148990256     PISSN: 01945998     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.otohns.2008.01.004     Document Type: Erratum

References (11)

1. Dykewicz M.S., Fineman S., and Working Group on Rhinitis. Diagnosis and management of rhinitis: complete guidelines of the joint task force on practice parameters in allergy, asthma, and immunology. Ann Allergy Asthma Immunol 81 (1998) 478-518
2. Hollingsworth H.M. Allergic rhinoconjunctivitis: current therapy. Hosp Pract 31 (1996) 61-62 65-7, 71-3
3. AAFA Allergy Survey (2005), Harris Interactive, Inc
4. Yanni J.M., Stephens D.J., Miller S.T., et al. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent. J Ocul Pharmacol Ther 12 (1996) 389-400
5. Abelson M.B., and Spitalny L. Combined analysis of two studies using conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity. Am J Ophthalmol 125 (1998) 797-804
6. U.S. Food and Drug Administration. Draft guidance for allergic rhinitis: clinical development programs for drug products (http://www.fda.gov/cder/index.html). Publication #2718dft, 2000; accessed June 2, 2006.
7. McNeeley W., and Wiseman L.R. Intranasal azelastine: a review of its efficacy in the management of allergic rhinitis. Drugs 56 (1998) 91-114
8. Neilsen L.P., and Dahl R. Comparison of intranasal corticosteroids and antihistamines in allergic rhinitis: a review of randomized, controlled trials. Am J Respir Med 2 (2003) 55-65
9. Ratner P.H., Hampel F.C., Amar N.J., et al. Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal (mountain cedar) allergic rhinitis. Ann Allergy Asthma Immunol 95 (2005) 474-479
10. Meltzer E.O., Hampel F.C., Ratner P.H., et al. Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 95 (2005) 600-606
11. Day J.H., Briscoe M.P., Rafeiro E., et al. Onset of action of intranasal budesonide (Rhinocort Aqua) in seasonal allergy rhinitis studied in a controlled exposure model. J Allergy Clin Immunol 105 (2000) 489-494